Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DECODE GENETICS-*DCGN -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (158)	12/17/2004 7:58:57 AM
From: nigel bates	Respond to of 313

deCODE to Conduct Phase II Clinical Trial in Asthma Friday December 17, 6:59 am ET A little more detail would have been nice...<g> REYKJAVIK, Iceland, Dec. 17 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN - News) today announced the signing of an agreement under which it will conduct a Phase II information-rich clinical trial next year of a third-party compound as part of a drug development program in asthma. The compound targetsthe product of a gene deCODE has shown to play an important role in the development of asthma. The trial will leverage deCODE's extensive population research in asthma and enrollment is expected to begin in early 2005. Neither the name of the company nor of the compound was disclosed. "This is another example of how our gene discovery work has led us to targets against which promising compounds have been developed by others in other indications. This approach enables us to leapfrog over several years of drug discovery and development and to go straight into information-rich trials, accelerating the application in the clinic of our gene discoveries and generating product-driven value for the company," said Kari Stefansson, CEO of deCODE...